Developer docs
API playgroundTry for free, no card

Search company profiles

Aurinia Pharmaceuticals

Full company profile

uuid0002m6s

Namestring
Aurinia Pharmaceuticals
Legal namestring
Aurinia Pharmaceuticals Inc.
Company typeenum
Public
Founded yearint
2012
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersEdmonton, Canada
HQ citystring
Edmonton
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
lupus nephritis treatment, oral calcineurin inhibitor, autoimmune disease therapeutics, biopharmaceutical drug development, voclosporin therapy
Industry3 codes
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Lupus Nephritis Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1LUPKYNIS Product Sales
TypeOne Time License
Description

Aurinia generates primary revenue from net product sales of LUPKYNIS (voclosporin), its FDA-approved oral therapy for active lupus nephritis. Q1 2026 net product sales were $73.6 million, representing 23% year-over-year growth. Full-year 2025 net product sales reached $271.3 million, growing 25% compared to 2024. 2026 guidance projects $305-315 million in net product sales.

stocktitan.net
2License and Royalty Revenue (Otsuka Partnership)
TypeLicensing Royalties
Description

Aurinia receives license, royalty, and collaboration revenue from its partnership with Otsuka for LUPKYNIS commercialization in Japan. Otsuka filed a New Drug Application (NDA) for voclosporin in Japan, and the product received regulatory approval in Japan in September 2024. Aurinia also expanded internationally with approvals in the UK, EU (European Commission), and Switzerland.

auriniapharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Pricing details1 tier
1LUPKYNIS (voclosporin) 23.7 mg twice daily dosing
ModelSubscriptionBilling cadenceMonthly
Notes

Recommended starting dose of three capsules twice daily with no requirement for serum drug monitoring. Specific pricing not publicly disclosed.

stocktitan.net
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1LUPKYNIS
Description

FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (voclosporin)

auriniapharma.com
+2 more records
Core offering1 text field

Aurinia Pharmaceuticals develops and commercializes LUPKYNIS (voclosporin), the first and only FDA-approved oral calcineurin inhibitor therapy for the treatment of adult patients with active lupus nephritis, generating net product sales of $271.3 million in 2025. The company also develops pipeline assets including aritinercept (AUR200), a dual BAFF/APRIL inhibitor, and zetomipzomib, a first-in-class immunoproteasome inhibitor acquired from Kezar Life Sciences in 2026, both targeting serious autoimmune diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 53% reduction in risk of renal-related event or death (hazard ratio=0.47; p=0.0007) in AURORA 1 post-hoc analysis at EULAR 2026
+3 more records
Product overview1 text field

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases. The company's commercial product portfolio centers on LUPKYNIS (voclosporin), the first FDA-approved oral therapy for active lupus nephritis, launched in January 2021. The pipeline includes aritinercept (AUR200), a dual BAFF/APRIL inhibitor in Phase 1 development for autoimmune diseases, and zetomipzomib, an immunoproteasome inhibitor acquired from Kezar Life Sciences in 2026 for autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus. The company operates from corporate headquarters in Edmonton, Alberta and U.S. commercial offices in Rockville, Maryland.

Product and service3 records
1LUPKYNIS (voclosporin)
CategoryCore commercial product
Description

LUPKYNIS is the first and only FDA-approved oral second-generation calcineurin inhibitor therapy for adult patients with active lupus nephritis. It has a dual mechanism of action: immunosuppression through inhibition of T-cell activation and cytokine production, combined with podocyte stability in the kidney. Recommended starting dose is three capsules twice daily with no requirement for serum drug monitoring.

2Aritinercept (AUR200)
CategoryPipeline product (clinical-stage)
Description

Aritinercept is a dual BAFF/APRIL inhibitor in clinical development for autoimmune diseases. It features a BCMA-engineered extracellular binding domain and IgG4 Fc domain, with binding affinities of 147 pM for BAFF and 28 pM for APRIL. Phase 1 study results support monthly dosing.

3Aurinia Alliance
CategoryPatient support program
Description

Aurinia Alliance is a patient support program providing resources, education, and assistance for patients prescribed LUPKYNIS, including access support, financial assistance, and ongoing patient education services.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeOthersAnnounced on2026-04-03
Description

Kezar Life Sciences agreed to sell certain assets to Enodia Therapeutics as part of the restructuring prior to its acquisition by Aurinia. The transaction involved potential milestone payments related to zetomipzomib development.

Strategic tierMinorTypeOthersAnnounced on2026-04-03
Description

Alliance Advisors served as Information Agent for Kezar Life Sciences' tender offer, which was acquired by Aurinia Pharmaceuticals. This was noted as Alliance's 10th successful tender offer for pharmaceutical and biotechnology companies in the past 12 months.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-12
Description

Otsuka is a collaboration partner for the commercialization and development of LUPKYNIS (voclosporin) in Japan. Otsuka filed a New Drug Application (NDA) for voclosporin in Japan, and the product received regulatory approval from Japan's PMDA in September 2024. The partnership expands Aurinia's international footprint and provides royalty revenue stream from Japanese sales.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aurinia Pharmaceuticals

Lupus Nephritis Therapeuticsauriniapharma.com

Aurinia Pharmaceuticals firmographics

Firmographics
Name
Aurinia Pharmaceuticals
Legal name
Aurinia Pharmaceuticals Inc.
Website
https://auriniapharma.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Aurinia Pharmaceuticals industry classification

Industry
Product category
Lupus Nephritis Therapeutics
NAICS
Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Lupus nephritis treatment
  • Oral calcineurin inhibitor
  • Autoimmune disease therapeutics
  • Biopharmaceutical drug development
  • Voclosporin therapy

Where Aurinia Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Edmonton
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Aurinia Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

  1. LUPKYNIS Product Sales: Aurinia generates primary revenue from net product sales of LUPKYNIS (voclosporin), its FDA-approved oral therapy for active lupus nephritis. Q1 2026 net product sales were $73.6 million, representing 23% year-over-year growth. Full-year 2025 net product sales reached $271.3 million, growing 25% compared to 2024. 2026 guidance projects $305-315 million in net product sales.
  2. License and Royalty Revenue (Otsuka Partnership): Aurinia receives license, royalty, and collaboration revenue from its partnership with Otsuka for LUPKYNIS commercialization in Japan. Otsuka filed a New Drug Application (NDA) for voclosporin in Japan, and the product received regulatory approval in Japan in September 2024. Aurinia also expanded internationally with approvals in the UK, EU (European Commission), and Switzerland.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyLUPKYNIS (voclosporin) 23.7 mg twice daily dosing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Aurinia Pharmaceuticals product offering

Product offering

Core offering

Aurinia Pharmaceuticals develops and commercializes LUPKYNIS (voclosporin), the first and only FDA-approved oral calcineurin inhibitor therapy for the treatment of adult patients with active lupus nephritis, generating net product sales of $271.3 million in 2025. The company also develops pipeline assets including aritinercept (AUR200), a dual BAFF/APRIL inhibitor, and zetomipzomib, a first-in-class immunoproteasome inhibitor acquired from Kezar Life Sciences in 2026, both targeting serious autoimmune diseases.

Product overview

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases. The company's commercial product portfolio centers on LUPKYNIS (voclosporin), the first FDA-approved oral therapy for active lupus nephritis, launched in January 2021. The pipeline includes aritinercept (AUR200), a dual BAFF/APRIL inhibitor in Phase 1 development for autoimmune diseases, and zetomipzomib, an immunoproteasome inhibitor acquired from Kezar Life Sciences in 2026 for autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus. The company operates from corporate headquarters in Edmonton, Alberta and U.S. commercial offices in Rockville, Maryland.

Differentiator

Problem solved

Functional benefit

Brands

  • LUPKYNIS: FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (voclosporin)
  • Aritinercept
  • Zetomipzomib

Products and services

  • LUPKYNIS (voclosporin) LUPKYNIS is the first and only FDA-approved oral second-generation calcineurin inhibitor therapy for adult patients with active lupus nephritis. It has a dual mechanism of action: immunosuppression through inhibition of T-cell activation and cytokine production, combined with podocyte stability in the kidney. Recommended starting dose is three capsules twice daily with no requirement for serum drug monitoring.
  • Aritinercept (AUR200) Aritinercept is a dual BAFF/APRIL inhibitor in clinical development for autoimmune diseases. It features a BCMA-engineered extracellular binding domain and IgG4 Fc domain, with binding affinities of 147 pM for BAFF and 28 pM for APRIL. Phase 1 study results support monthly dosing.
  • Aurinia Alliance Aurinia Alliance is a patient support program providing resources, education, and assistance for patients prescribed LUPKYNIS, including access support, financial assistance, and ongoing patient education services.

Quantifiable outcome

  • 53% reduction in risk of renal-related event or death (hazard ratio=0.47; p=0.0007) in AURORA 1 post-hoc analysis at EULAR 2026
  • +3 more outcomes

Companies that use Aurinia Pharmaceuticals

Customer profile

Segments2 records

Ideal customer profiles2 records

Aurinia Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Aurinia Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • Enodia TherapeuticsminorOthers · 3 April 2026Kezar Life Sciences agreed to sell certain assets to Enodia Therapeutics as part of the restructuring prior to its acquisition by Aurinia. The transaction involved potential milestone payments related to zetomipzomib development.
  • Alliance AdvisorsminorOthers · 3 April 2026Alliance Advisors served as Information Agent for Kezar Life Sciences' tender offer, which was acquired by Aurinia Pharmaceuticals. This was noted as Alliance's 10th successful tender offer for pharmaceutical and biotechnology companies in the past 12 months.
  • OtsukacoreStrategic or Co-development Partner · 12 October 2023Otsuka is a collaboration partner for the commercialization and development of LUPKYNIS (voclosporin) in Japan. Otsuka filed a New Drug Application (NDA) for voclosporin in Japan, and the product received regulatory approval from Japan's PMDA in September 2024. The partnership expands Aurinia's international footprint and provides royalty revenue stream from Japanese sales.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Aurinia Pharmaceuticals competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Aurinia Pharmaceuticals social profiles

Digital presence

Aurinia Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aurinia Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles7 records

Aurinia Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Aurinia Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aurinia Pharmaceuticals M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aurinia Pharmaceuticals

What does Aurinia Pharmaceuticals do?

Aurinia Pharmaceuticals develops and commercializes LUPKYNIS (voclosporin), the first and only FDA-approved oral calcineurin inhibitor therapy for the treatment of adult patients with active lupus nephritis, generating net product sales of $271.3 million in 2025. The company also develops pipeline assets including aritinercept (AUR200), a dual BAFF/APRIL inhibitor, and zetomipzomib, a first-in-class immunoproteasome inhibitor acquired from Kezar Life Sciences in 2026, both targeting serious autoimmune diseases.

Is Aurinia Pharmaceuticals a public or private company?

Aurinia Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Aurinia Pharmaceuticals founded?

Aurinia Pharmaceuticals was founded in 2012. It employs 101 to 250 people.

Where is Aurinia Pharmaceuticals based?

Aurinia Pharmaceuticals is headquartered in Edmonton, Canada, in the North America region.

How does Aurinia Pharmaceuticals make money?

Two revenue lines are on record. LUPKYNIS Product Sales are the primary driver. The others are license and Royalty Revenue (Otsuka Partnership).

Does Aurinia Pharmaceuticals have an API?

No public API is recorded for Aurinia Pharmaceuticals.

What industry is Aurinia Pharmaceuticals in?

Aurinia Pharmaceuticals's product category is Lupus Nephritis Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies. Its NAICS code is 5417 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StWill Raised Revenue Guidance Change Aurinia Pharmaceuticals Stock NarrativeAurinia Pharmaceuticals reported Q3 2026 revenue of $83.7 million and net income of $31.7 million, with nine-month revenue of $244.62 million. Management raised full-year 2026 revenue guidance to $325-330 million, reaffirming its cash-generative business model. The raised guidance supports the short-term narrative but does not remove concerns about LUPKYNIS pricing pressure.American Banking and Market NewsAurinia Pharmaceuticals (NASDAQ:AUPH) Stock Gets Downgrade from Wall Street ZenWall Street Zen downgraded Aurinia Pharmaceuticals from buy to hold, while other analysts issued mixed ratings. The stock opened at $16.46, with a consensus rating of Moderate Buy and an average target price of $17.33. The company reported Q3 EPS of $0.23, beating estimates.American Banking and Market NewsAurinia Pharmaceuticals (NASDAQ:AUPH) Stock Gets Price Target Bump from Royal Bank Of CanadaRoyal Bank of Canada raised Aurinia Pharmaceuticals' price target to $18 from $16, citing a sector perform rating. The stock opened at $16.56, with an average analyst price target of $18.25. The company reported Q3 EPS of $0.23, beating estimates.TradingViewRBC Capital maintains Aurinia Pharmaceuticals at Sector Perform, raises price target to $18 from $16RBC Capital maintained Aurinia Pharmaceuticals at Sector Perform and raised its price target to $18 from $16, a 12.5% increase. The target implies an 8.1% upside from the Oct 30 close of $16.65.MarketBeatAurinia Pharmaceuticals (NASDAQ:AUPH) Issues Earnings ResultsAurinia Pharmaceuticals reported quarterly EPS of $0.23, beating estimates of $0.22, with revenue of $83.70 million. Shares fell 3% to $16.69, and analysts have a consensus Moderate Buy rating with a $17.75 price target.Investing.comAurinia Pharmaceuticals stock falls 3% on Q3 miss, soft guidanceAurinia Pharmaceuticals reported Q3 adjusted EPS of $0.23, missing the $0.24 consensus, and revenue of $83.7 million, slightly below the $84.0 million estimate. The company raised its full-year 2026 revenue guidance to $325–330 million, though the midpoint remains below analyst consensus. It also initiated a Phase 4 study combining LUPKYNIS with other drugs for lupus nephritis.Financial PostAurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business ProgressAurinia Pharmaceuticals reported total revenue of $83.7 million for the three months and $244.6 million for nine months ended September 30, 2026, up 14% and 19% from 2025. Net income was $31.7 million for the quarter and $103.5 million for nine months, flat and up 35% respectively. The company raised its 2026 revenue guidance to $325–330 million.TradingViewAUPH: LUPKYNIS growth, $486.9 million in cash and investments, and broader clinical development. document-source1716Aurinia Pharmaceuticals reported Q3 revenue of $83.7 million and net income of $31.7 million, with LUPKYNIS sales rising 12% year-over-year. The company held $486.9 million in cash and investments, and development advanced across PRESERVE and four aritinercept indications.TradingViewAUPH: Higher 2026 revenue guidance accompanies rising sales and earningsAurinia Pharmaceuticals raised its 2026 revenue guidance, citing Q3 revenue up 14% year-over-year and net income up 35%. The company also advanced its Phase 4 combination study and expanded aritinercept development to four indications.Quiver QuantitativeAurinia Q3 Revenue Rises 14% to $83.7 Million, Raises 2026 Outlook | AUPH Stock NewsAurinia Pharmaceuticals reported Q3 2026 revenue of $83.7 million, up 14% year over year, with net income of $31.7 million. The company raised its 2026 revenue guidance to $325–330 million and initiated a Phase 4 study for LUPKYNIS in lupus nephritis.